NCT07900165Not yet recruitingPhase 1/2
Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer
A Trial of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Participants With Metastatic Colorectal Cancer
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
This is a non-registrational Phase 1/2, multicenter, open-label trial to evaluate the efficacy and safety of varsetatug masetecan combined with anti-cancer therapies in participants with unresectable metastatic colorectal cancer in the second line treatment setting.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 368 (estimated)
- First submitted
- 21 Oct 2026
- Start date
- Dec 2026
- Primary completion date
- Feb 2029
- Lead sponsor
- CytomX Therapeutics
- Diseases
- Colorectal cancer
- NCT number
- NCT07900165
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 368
- From Dec 2026 to the primary completion date, Feb 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants with prior CNS involvement with malignancy must have completed effective treatment of their CNS disease at least 4 weeks prior to first dose of trial intervention
- Serious concurrent illness
- Prior treatment with ADCs with Topo-I inhibitor payload
- Prior treatment with irinotecan or Topo-I inhibitors
- Receipt of systemic anti-cancer treatment, radiotherapy, or investigational agent(s) within 14days prior to trial intervention initiation
- Surgery within 4 weeks prior to first dose of trial intervention
Other illness
- Recent history (within last 2 years) of localized cancers that are not related to the current cancer being treated
Other
- Clinically significant proteinuria
- Pregnant or breastfeeding
- Additional exclusion criteria may apply
Who the study is looking for
- Histologically or cytologically documented unresectable metastatic CRC
- Documented progression during or following exactly one prior regimen of systemic therapy with or without targeted therapy for metastatic CRC
- Measurable disease per RECIST v1.1
- Eastern Cooperative Oncology Group performance status of 0-1
- Adequate organ and marrow function
- Additional inclusion criteria may apply
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.